Full-Time

Senior Manager

Regulatory Affairs

Braveheart Bio

Braveheart Bio

11-50 employees

Develops cardiac myosin inhibitors for HCM

Compensation Overview

$119k - $190k/yr

+ Annual Bonus + Equity

San Francisco, CA, USA

Hybrid

Hybrid role; occasional on-site presence in San Francisco, CA may be required.

Bachelor's, Master's, PharmD, PhD

Category
Legal & Compliance (1)

Get referred to Braveheart Bio

See people who can refer or advise you

Requirements
  • Bachelor’s degree
  • Minimum of 5 years of regulatory affairs experience in biotech or pharmaceutical drug development, with a strong focus on EU and ex-U.S. clinical trial submissions
  • Demonstrated hands-on experience with EU CTA submissions in CTIS, CTA preparation and coordination, health authority interactions and response management
  • Strong knowledge of EU regulatory frameworks including EU CTR 536/2014, EMA guidance and CTA requirements, and applicable ICH guidelines
  • Experience managing CTA lifecycle activities (amendments, updates, and maintenance)
  • Strong project management and organizational skills, with ability to work independently, manage multiple priorities, and meet deadlines in a lean, fast-paced environment
  • Demonstrated ability to write clear, accurate regulatory documents
  • Detail-oriented with a commitment to quality and compliance
  • Strong written and verbal communication skills with a collaborative, team-oriented approach
  • Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity
  • Flexible, proactive, and hands-on mindset with a roll-up-your-sleeves, can-do attitude
Responsibilities
  • EU and Ex-U.S. CTA Preparation, Execution, and Life-cycle Management
  • Manage the preparation, compilation, and submission of CTAs, including CTIS submissions and country-specific applications
  • Ensure CTA packages include all required documents (e.g., protocol, IB, IMPD, ICFs) and meet regional and country-specific requirements
  • Provide regulatory guidance on EU CTR, CTIS processes, and country-specific CTA requirements
  • Manage health authority questions and sponsor responses to support timely approvals
  • Support CTA maintenance activities, including substantial modifications, protocol amendments, IMPD updates, quality changes, annual updates, and notifications
  • Track submission status and maintain inspection-ready documentation and regulatory archives
  • Partner closely with Clinical Development and Clinical Operations to support global study start-up timelines
  • Collaborate with CMC and Quality teams to ensure accurate and compliant IMPD and quality documentation
  • Serve as a regulatory liaison across internal teams and external partners to ensure timely and compliant submissions across ex-U.S. markets
Desired Qualifications
  • Advanced degree (MS, PhD, PharmD)
  • Experience with regulatory submissions in the U.S. (FDA) and other ex-U.S. regions such as the UK (MHRA), Canada (Health Canada), Australia (TGA), South Korea (MFDS), or LATAM
  • Experience supporting the preparation of marketing applications (e.g., NDAs and MAAs)
  • Experience in cardiovascular, rare disease, or small molecule drug development
  • Familiarity with CMC regulatory requirements in ex-U.S. regions and the ability to review and contribute to quality sections of regulatory dossiers
  • Experience with Veeva RIM or similar document management systems

Braveheart Bio develops therapeutics for hypertrophic cardiomyopathy by in-licensing and advancing late-stage drug candidates. Its lead drug, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from Hengrui Pharma for ex-China rights in a deal worth up to $1.1 billion, aimed at improving heart function by tempering myosin activity in HCM. The program includes Phase 2 trials in obstructive and non-obstructive HCM and a Phase 3 trial in China, with global late-stage development planned to begin in 2026. The company differentiates itself by pursuing a best-in-class profile with better efficacy, safety, and dosing, supported by a strong leadership team and high-profile investors, with the goal of delivering an approved therapy that provides meaningful clinical benefit and broader global access.

Company Size

11-50

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2025

Get referred to Braveheart Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 7, 2026 IPO raised $382.5 million, extending runway.
  • March and May 2026 Phase 2 data showed rapid gradient and biomarker improvements.
  • Global Phase 3 trials start in 2026, creating near-term catalysts.

What critics are saying

  • Camzyos and Cytokinetics' aficamten already occupy the HCM race in 2026.
  • Braveheart depends on Hengrui for IP, history, and clinical evidence.
  • If Phase 3 fails in 2026-2027, BRVE becomes a single-asset dead end.

What makes Braveheart Bio unique

  • BHB-1893 is Hengrui-proven, giving Braveheart Phase 2 and Phase 3 human data.
  • Travis Murdoch and Chris Viehbacher bring HI-Bio and Biogen execution credibility.
  • The company targets HCM with simpler dosing than Bristol Myers Squibb's Camzyos.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

6%

2 year growth

6%
Endpoints News
Aug 6th, 2026
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3.

Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3. Biotech correspondent. For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

MarketScreener
Aug 6th, 2026
Braveheart Bio prices upsized $382.5M IPO for heart disease therapies

Braveheart Bio, a clinical-stage biopharmaceutical company developing therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases, has priced its upsized initial public offering at $18.00 per share. The San Francisco-based company is offering 21,250,000 shares, with expected gross proceeds of $382.5 million before deducting underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market on 6 August 2026 under the ticker symbol "BRVE". The offering is scheduled to close on 7 August 2026, subject to customary closing conditions. Braveheart Bio has granted underwriters a 30-day option to purchase up to an additional 3,187,500 shares. Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are serving as joint book-running managers.

PR Newswire
Mar 26th, 2026
Braveheart Bio appoints Emil deGoma as CMO ahead of 2026 pivotal trial for BHB-1893

Braveheart Bio has appointed Emil deGoma, M.D., as Chief Medical Officer to lead clinical strategy and medical affairs as the company advances BHB-1893 towards a planned global pivotal trial in obstructive hypertrophic cardiomyopathy in 2026. DeGoma joins from Tourmaline Bio, where he served as Senior Vice President of Medical Research. He previously held leadership positions at Akebia Therapeutics, overseeing cardiovascular outcomes trials with over 7,000 patients, and at ChemoCentryx and Penn Medicine. He completed his cardiovascular medicine fellowship at Stanford University and is a Fellow of the American College of Cardiology. Braveheart Bio is a clinical-stage biotechnology company backed by investors including Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences and Frazier Life Sciences.

The Pharma Letter
Mar 26th, 2026
Emil deGoma named Braveheart CMO.

Emil deGoma named Braveheart CMO. 26 March 2026 Braveheart Bio, a US biotech developing therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced the appointment of Emil deGoma (pictured, above) as chief medical officer (CMO). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 5 February 2026 6 November 2025 13 March 2026 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 29 March 2026 28 March 2026 27 March 2026 Company spotlight. A biotech firm developing a novel class of allergy therapies known as Trifunctional Effector Cell Response Inhibitors (ECRIs). More features in biotechnology. 28 March 2026 27 March 2026

PR Newswire
Feb 5th, 2026
Braveheart Bio appoints Marc Evanchik as chief scientific officer ahead of Phase 3 trial launch

Braveheart Bio has appointed Marc Evanchik as Chief Scientific Officer and Brittany de Temple as Senior Vice President of Development Operations as it prepares for a planned global Phase 3 trial in obstructive hypertrophic cardiomyopathy in 2026. Evanchik, promoted from his previous role, brings over 25 years of biotech experience and was instrumental in advancing Camzyos, the first-in-class cardiac myosin inhibitor. He will lead scientific strategy from target discovery through late-stage development for the company's lead programme, BHB-1893. De Temple joins from Akero Therapeutics with more than 20 years of clinical development operations experience. She will oversee operational strategy and execution of Braveheart's expanding clinical programmes. The San Francisco-based company is backed by investors including Andreessen Horowitz and OrbiMed.